Angela M. Barbara, Lindsay Ritchie, Melissa Severn
{"title":"Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle","authors":"Angela M. Barbara, Lindsay Ritchie, Melissa Severn","doi":"10.51731/cjht.2024.847","DOIUrl":null,"url":null,"abstract":"What Is the Issue? \n \nOsteoarthritis (OA) is a chronic disease of the joints, such as the hip, shoulder, and ankle. OA causes the joints to be painful, unstable, and less functional. In adults 55 years and younger, joint trauma is a common cause of OA. \nHyaluronic acid (HA) is a naturally occurring molecule found in human cells that provides lubrication when injected into the joint. HA injections are a less invasive option than surgery, with potentially fewer complications. \nTo support decision-making about treating hip, shoulder, or ankle OA in adults 55 years and younger, it is important to understand the potential benefits and harms of using HA in this population. \n \nWhat Did We Do? \n \nWe reviewed the clinical effectiveness of high molecular weight (MW) injection of HA in adults between the ages of 18 and 55 years with OA of the hip, shoulder, or ankle joints to guide decisions on the use of high MW HA injection. \nAn information specialist searched for peer-reviewed and grey literature sources published on January 1, 2013 to December 12, 2023. One reviewer screened citations and selected and critically appraised the included studies. \n \nWhat Did We Find? \n \nThe evidence for this report was based on observational before-and-after studies. We found no relevant comparative studies examining the effect of high MW HA versus placebo or no treatment. \nWhile most studies reported post-treatment outcome improvements, it is uncertain whether high MW injection of HA improves pain, function, and disability in adults 55 years and under with hip, shoulder, or ankle OA. This is due to the low-quality evidence, small sample sizes, and methodological problems. Serious side effects of high MW HA were not reported. \n \nWhat Does This Mean? \n \nDue to the uncertainty of the clinical effectiveness evidence, health care providers and decision-makers may consider other factors when considering high MW IA-HA for patients with hip, shoulder, or ankle OA; these factors could include acceptability, feasibility, costs, health equity, and patient values and preferences. \nFuture research from randomized studies in large populations is needed to understand the effectiveness and safety of high MW HA injections for hip, shoulder, and ankle OA. \n","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"24 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2024.847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
What Is the Issue?
Osteoarthritis (OA) is a chronic disease of the joints, such as the hip, shoulder, and ankle. OA causes the joints to be painful, unstable, and less functional. In adults 55 years and younger, joint trauma is a common cause of OA.
Hyaluronic acid (HA) is a naturally occurring molecule found in human cells that provides lubrication when injected into the joint. HA injections are a less invasive option than surgery, with potentially fewer complications.
To support decision-making about treating hip, shoulder, or ankle OA in adults 55 years and younger, it is important to understand the potential benefits and harms of using HA in this population.
What Did We Do?
We reviewed the clinical effectiveness of high molecular weight (MW) injection of HA in adults between the ages of 18 and 55 years with OA of the hip, shoulder, or ankle joints to guide decisions on the use of high MW HA injection.
An information specialist searched for peer-reviewed and grey literature sources published on January 1, 2013 to December 12, 2023. One reviewer screened citations and selected and critically appraised the included studies.
What Did We Find?
The evidence for this report was based on observational before-and-after studies. We found no relevant comparative studies examining the effect of high MW HA versus placebo or no treatment.
While most studies reported post-treatment outcome improvements, it is uncertain whether high MW injection of HA improves pain, function, and disability in adults 55 years and under with hip, shoulder, or ankle OA. This is due to the low-quality evidence, small sample sizes, and methodological problems. Serious side effects of high MW HA were not reported.
What Does This Mean?
Due to the uncertainty of the clinical effectiveness evidence, health care providers and decision-makers may consider other factors when considering high MW IA-HA for patients with hip, shoulder, or ankle OA; these factors could include acceptability, feasibility, costs, health equity, and patient values and preferences.
Future research from randomized studies in large populations is needed to understand the effectiveness and safety of high MW HA injections for hip, shoulder, and ankle OA.
问题是什么? 骨关节炎(OA)是髋关节、肩关节和踝关节等关节的一种慢性疾病。OA 会导致关节疼痛、不稳定和功能减退。在 55 岁及以下的成年人中,关节创伤是导致 OA 的常见原因。透明质酸(HA)是一种存在于人体细胞中的天然分子,注入关节后可起到润滑作用。与手术相比,注射透明质酸是一种创伤较小的选择,并发症也可能较少。为了帮助 55 岁及以下的成年人做出治疗髋关节、肩关节或踝关节 OA 的决策,了解在这一人群中使用 HA 的潜在益处和弊端非常重要。 我们做了什么? 我们回顾了高分子量(MW)HA注射剂对18至55岁患有髋关节、肩关节或踝关节OA的成年人的临床疗效,以指导使用高分子量HA注射剂的决策。一位信息专家检索了2013年1月1日至2023年12月12日发表的同行评议和灰色文献资料。一位审稿人筛选了引文,并对纳入的研究进行了筛选和严格评估。 我们发现了什么? 本报告的证据基于观察性前后对比研究。我们没有发现任何相关的比较研究,对高分子量 HA 与安慰剂或不治疗的效果进行检查。虽然大多数研究报告了治疗后的效果改善情况,但目前尚不确定高分子量注射HA是否能改善55岁及以下患有髋关节、肩关节或踝关节OA的成年人的疼痛、功能和残疾状况。这主要是由于证据质量低、样本量小以及方法问题。没有关于高MW HA严重副作用的报道。 这意味着什么? 由于临床有效性证据的不确定性,医疗服务提供者和决策者在考虑为髋关节、肩关节或踝关节OA患者提供高分子量IA-HA时可能会考虑其他因素;这些因素可能包括可接受性、可行性、成本、健康公平性以及患者的价值观和偏好。未来需要对大量人群进行随机研究,以了解高分子量 HA 注射治疗髋关节、肩关节和踝关节 OA 的有效性和安全性。